Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.

Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. Clin Cancer Res. 2020 10 01; 26(19):5153-5161.

View in: PubMed

subject areas

Adult
Aged
Antibodies, Monoclonal, Humanized
Biological Products
Combined Modality Therapy
Drug-Related Side Effects and Adverse Reactions
Female
Herpesvirus 1, Human
Humans
Immunotherapy
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Recurrence, Local
Oncolytic Virotherapy

authors with profiles

Ezra Cohen